In an attempt to challenge myself, I took my first non-business trip by myself in the summer of 2019 and walked 80 miles of the Camino de Santiago and then went to surf school (note: I was not a capable student/surfer).
Before joining Relay Therapeutics, Tara O’Meara spent nearly a decade at bluebird bio, initially overseeing the development and execution of the clinical program for a rare genetic disease, and most recently, leading the clinical development operations department where she had strategic oversight across all development portfolio, including severe genetic disease and oncology. Prior to bluebird bio, Tara directed the clinical operations group for Synageva BioPharma, now Alexion Pharmaceuticals, and held multiple roles at the Genzyme Corporation, now Sanofi Genzyme, including global team leader for a clinical development program in Pompe disease. Tara has been responsible for everything from small Phase II trials to very large, global Phase III trials in multiple therapeutic areas.
Tara holds a BS in biology and a certificate in women’s studies from Tufts University. Tara also completed the Emerging Leaders Program at University Massachusetts, Boston in 2010.